Revance is a clinical-stage biotechnology company that specializes in innovative aesthetic and therapeutic offerings built around peptide-enhanced neuromodulator technology. The organisation employs roughly 550 people and its most recent talent data shows nearly 90 new additions offset by a similar level of departures, keeping overall headcount steady. This balanced hiring and attrition pattern suggests Revance is maintaining a consistent workforce size while it advances product development and commercial efforts.
Revance’s talent pool is concentrated in several core functions that support research, development, and commercial execution. Healthcare roles—encompassing clinical, medical, and regulatory specialists—form the largest single group at roughly 19 percent of staff. Sales & Support follows closely at about 18 percent, underpinning commercial outreach as the company brings products to market. Engineering talent accounts for just under 15 percent of employees, reflecting the technical requirements of drug formulation and delivery platforms. Marketing & Product (8 percent), Business Management (7 percent), Finance & Administration (7 percent), and Operations (7 percent) round out the key teams, while a small number of employees serve in editorial or other specialized capacities.
Employee records show Revance has a distributed footprint with concentrations in several U.S. life-science hubs. San Francisco hosts the largest cohort at close to 19 percent of the workforce, aligning with the region’s strong biotech ecosystem. Nashville is the second-largest site at roughly 11 percent, providing access to healthcare talent and a central U.S. location. Smaller offices and field teams are based in Los Angeles, Irvine, New York, Pleasanton, San Jose, San Diego, and Boston, each accounting for between 1 and 3 percent of headcount, while an "Other" category covers additional remote or satellite staff. This geographic mix gives Revance access to diverse talent pools and positions the company near key clinical, regulatory, and commercial partners.